Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 19/20 | 0.59 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16031735 | 0.84 | NR1H2 (0.43) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL21147087 | 0.83 | NR1H2 (0.51) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL14816842 | 0.83 | NR1H2 (0.45) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL17022654 | 0.82 | NR1H2 (0.57) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL20683662 | 0.82 | NR1H2 (0.53) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL1079096 | 0.81 | NR1H2 (0.54) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL16090764 | 0.81 | NR1H2 (0.48) | NR1H2NR1H3 | |
| SCHEMBL16090783 | 0.81 | NR1H2 (0.40) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL4760328 | 0.80 | NR1H2 (0.68) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL16030138 | 0.80 | NR1H2 (0.47) | NR1H2NR1H3CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060093666-A1 | Formulations for tyrosine kinase inhibitors | MERCK & CO., INC. | 2006-05-04 | — | — | US | disclosed |
| CN-1764381-A | The preparation that is used for tyrosine kinase inhibitor | MERCK & CO INC (US) | 2006-04-26 | — | — | CN | disclosed |
| EP-1610614-A2 | FORMULATIONS FOR TYROSINE KINASE INHIBITORS | Merck & Co. Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004087651-A2 | FORMULATIONS FOR TYROSINE KINASE INHIBITORS | MERCK & CO. INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20020198252-A1 | Process for the preparation of alkylamine substituted indoles | PAYACK JOSEPH (US) | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060093666-A1 | Formulations for tyrosine kinase inhibitors | ABL1, ERBB2, JAK1 | NR1H2 4838/4885NR1H3 4861/4885CA12 4877/4885 |
| US-20020198252-A1 | Process for the preparation of alkylamine substituted indoles | INMT, IDO1, ABL1 | NR1H2 2886/4885NR1H3 2622/4885CA12 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.